Home Other Building Blocks Butyl-biguanidehydrochloride

Butyl-biguanidehydrochloride

CAS No.:
1190-53-0
Catalog Number:
AG000P0C
Molecular Formula:
C6H16ClN5
Molecular Weight:
193.6777
Pack Size
Purity
Availability
Location
Price(USD)
Quantity
  
25mg
98%(HPLC)
In Stock USA
United States
$68
- +
100mg
98%(HPLC)
In Stock USA
United States
$110
- +
250mg
98%(HPLC)
In Stock USA
United States
$233
- +
500mg
98%(HPLC)
In Stock USA
United States
$426
- +
Product Description
Catalog Number:
AG000P0C
Chemical Name:
Butyl-biguanidehydrochloride
CAS Number:
1190-53-0
Molecular Formula:
C6H16ClN5
Molecular Weight:
193.6777
MDL Number:
MFCD00045591
IUPAC Name:
2-butyl-1-(diaminomethylidene)guanidine;hydrochloride
InChI:
InChI=1S/C6H15N5.ClH/c1-2-3-4-10-6(9)11-5(7)8;/h2-4H2,1H3,(H6,7,8,9,10,11);1H
InChI Key:
KKLWSPPIRBIEOV-UHFFFAOYSA-N
SMILES:
CCCCNC(=N)NC(=N)N.Cl
UNII:
D947SXO87P
Properties
Complexity:
156  
Compound Is Canonicalized:
Yes
Covalently-Bonded Unit Count:
2  
Defined Atom Stereocenter Count:
0
Defined Bond Stereocenter Count:
0
Exact Mass:
193.109g/mol
Formal Charge:
0
Heavy Atom Count:
12  
Hydrogen Bond Acceptor Count:
1  
Hydrogen Bond Donor Count:
4  
Isotope Atom Count:
0
Molecular Weight:
193.679g/mol
Monoisotopic Mass:
193.109g/mol
Rotatable Bond Count:
4  
Topological Polar Surface Area:
103A^2
Undefined Atom Stereocenter Count:
0
Undefined Bond Stereocenter Count:
0
Literature
Title Journal
Biguanide-induced mitochondrial dysfunction yields increased lactate production and cytotoxicity of aerobically-poised HepG2 cells and human hepatocytes in vitro. Toxicology and applied pharmacology 20081201
Determination of antihyperglycemic biguanides in serum and urine using an ion-pair solid-phase extraction technique followed by HPLC-UV on a pentafluorophenylpropyl column and on an octadecyl column. Biomedical chromatography : BMC 20061101
Buformin suppresses the expression of glyceraldehyde 3-phosphate dehydrogenase. Biological & pharmaceutical bulletin 20060501
Effect of buformin and metformin on formation of advanced glycation end products by methylglyoxal. Clinica chimica acta; international journal of clinical chemistry 20050801
[A case of lactic acidosis caused by buformin in an oldest elderly diabetic patient]. Nihon Ronen Igakkai zasshi. Japanese journal of geriatrics 20050301
[A new case of lactic acidosis caused by buformin]. Anales de medicina interna (Madrid, Spain : 1984) 20050201
Short-term effect of buformin, a biguanide, on insulin sensitivity, soluble fraction of tumor necrosis factor receptor and serum lipids in overweight patients with type 2 diabetes mellitus. Diabetes research and clinical practice 20041101
Buformin-induced lactic acidosis--a symptom of modern healthcare malady. Journal of the American Geriatrics Society 20041001
A validated HPLC method with ultraviolet detection for the determination of buformin in plasma. Biomedical chromatography : BMC 20040501
Plasma BNP levels in the treatment of type 2 diabetes with pioglitazone. The Journal of clinical endocrinology and metabolism 20030801
[Lactic acidosis associated with buformine use]. Revista clinica espanola 20030401
Insulin and longevity: antidiabetic biguanides as geroprotectors. Biogerontology 20030101
Enhanced secretion of glucagon-like peptide 1 by biguanide compounds. Biochemical and biophysical research communications 20021115
A new method for determination of buformin in plasma and urine by ion-paired reversed-phase HPLC with ultraviolet detection. Biomedical chromatography : BMC 20021001
[Clinical usefulness of treatment with biguanide and insulin]. Nihon rinsho. Japanese journal of clinical medicine 20020901
Acrylic microspheres for oral controlled release of the biguanide buformin. International journal of pharmaceutics 20010507
Buformin concentrations in a case of fatal lactic acidosis. Diabetologia 19810101
[Lactic acidosis--a possible complication in buformin-treated diabetics (author's transl)]. Klinische Wochenschrift 19780901
Properties